/PRNewswire/ Perceive Biotherapeutics, a biotech company pioneering novel technologies and therapeutics in ophthalmology, today announced the appointment of.
Longer-term data from the DERBY and OAKS phase 3 studies showed that pegcetacoplan continued to reduce geographic atrophy lesion growth in patients with GA secondary to age-related macular degeneration.